open access

Vol 48, No 3 (2017)
Prace poglądowe / Reviews
Published online: 2017-07-01
Submitted: 2017-07-18
Get Citation

Ixazomib in patients with relapsed/refractory multiple myeloma

Krzysztof Giannopoulos12, Wiesław Wiktor Jędrzejczak3, Krzysztof Jamroziak4, Dominik Dytfeld5, Tadeusz Robak6, Andrzej Hellmann7
DOI: 10.1016/j.achaem.2017.07.002
·
Acta Haematol Pol 2017;48(3):160-164.
Affiliations
  1. Oddział Hematologiczny Centrum Onkologii Ziemi Lubelskiej, Lublin, Polska
  2. Zakład Hematoonkologii Doświadczalnej, Uniwersytet Medyczny w Lublinie, Lublin, Polska
  3. Klinika Hematologii, Onkologii i Chorób Wewnętrznych WUM, Warszawa, Polska
  4. Klinika Hematologii, Instytut Hematologii i Transfuzjologii, Warszawa, Polska
  5. Klinika Hematologii i Transplantacji Szpiku, UM w Poznaniu, Poznań, Polska
  6. Klinika Hematologii UM w Łodzi, Łódź, Polska
  7. Katedra i Klinika Hematologii i Transplantologii, Gdański Uniwersytet Medyczny, Gdańsk, Polska

open access

Vol 48, No 3 (2017)
Prace poglądowe / Reviews
Published online: 2017-07-01
Submitted: 2017-07-18

Abstract

Ixazomib is a new agent registered in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is the first oral proteasome inhibitor. Registration data show improvement in progression-free survival time (20.6 vs 14.7 months, p=0.01) but recent analysis in Asian population also in overall survival (25.8 vs 15.8 months, HR=0.419, p=0.001) what placed with lack of ixazomib incremental toxicity may implicate clinical importance of the treatment in relapsed or refractory multiple myeloma. Oral dosing of the triplet regimen may decrease the number and duration of hospitalizations that allows for better social functioning and occupational performance, and thus impacts daily disease perception.

Abstract

Ixazomib is a new agent registered in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is the first oral proteasome inhibitor. Registration data show improvement in progression-free survival time (20.6 vs 14.7 months, p=0.01) but recent analysis in Asian population also in overall survival (25.8 vs 15.8 months, HR=0.419, p=0.001) what placed with lack of ixazomib incremental toxicity may implicate clinical importance of the treatment in relapsed or refractory multiple myeloma. Oral dosing of the triplet regimen may decrease the number and duration of hospitalizations that allows for better social functioning and occupational performance, and thus impacts daily disease perception.

Get Citation

Keywords

Ixazomib; Multiple Myeloma; Treatment

About this article
Title

Ixazomib in patients with relapsed/refractory multiple myeloma

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 3 (2017)

Pages

160-164

Published online

2017-07-01

DOI

10.1016/j.achaem.2017.07.002

Bibliographic record

Acta Haematol Pol 2017;48(3):160-164.

Keywords

Ixazomib
Multiple Myeloma
Treatment

Authors

Krzysztof Giannopoulos
Wiesław Wiktor Jędrzejczak
Krzysztof Jamroziak
Dominik Dytfeld
Tadeusz Robak
Andrzej Hellmann

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl